多嚢胞性卵巣症候群の世界市場-2023年～2030年

市場概要

多嚢胞性卵巣症候群の世界市場は、2022年に31億米ドルに達し、2030年には46億米ドルに達するなど、有利な成長が予測されています。世界の多嚢胞性卵巣症候群市場は、2023年から2030年の予測期間中に5.5%のCAGRを示すと予測されています。

多嚢胞性卵巣症候群の症例数の増加、危険因子の有病率の増加、認知度の向上、資金援助イニシアティブ、検索活動の増加、有利な償還政策、製品の上市、製品認可、提携、買収、連合、拡大などの市場開拓などが、予測期間における世界の多嚢胞性卵巣症候群市場の成長を後押しすると予想されます。この市場における主要な市場プレイヤーには、Bayer AG、Pfizer Inc、Teva Pharmaceutical Industries Limited、Novartis、武田薬品工業などが含まれます。

市場力学

多嚢胞性卵巣症候群の症例増加が多嚢胞性卵巣症候群市場の成長を牽引

多嚢胞性卵巣症候群（PCOS）は、主に思春期以降の女性に影響を与える典型的な内分泌・ホルモン疾患です。あるいは、PCOSは多嚢胞性卵巣症候群として発症することもあります。生殖年齢層の女性の約5～15％が、月経異常、卵巣嚢腫、不妊症、さらに心血管障害、2型糖尿病（T2DM）、子宮内膜がんを含む健康問題を引き起こすホルモン不均衡に遭遇します。

世界保健機関（WHO）のデータによると、世界中でおよそ1億1600万人（3.4％）の女性がPCOSの影響を受けています。さらに、PCOS啓発協会によると、PCOSは米国で700万人以上の女性に影響を及ぼしており、これは乳がん、関節リウマチ、多発性硬化症、ループスと診断された女性の数を合わせた数よりも多いです。

研究資金の増加は、世界の多嚢胞性卵巣症候群市場に成長機会をもたらすと期待されています

研究資金の増加は、将来的に世界市場に有利な成長機会をもたらしています。例えば、2019-2020年までの最新の5会計年度において、NIHRとUKRIは子宮内膜症の調査のために852万ポンド、多嚢胞性卵巣症候群の調査のために660万ポンドを付与しています。これは、基礎科学から、診断、治療、支援提供に関する応用健康調査まで、幅広い課題を包含しています。

治療による副作用は、予測期間中、世界の多嚢胞性卵巣症候群市場の妨げになると予測されます

多嚢胞性卵巣症候群の治療によって引き起こされる副作用は、予測期間中の世界市場の成長を妨げます。例えば、多嚢胞性卵巣症候群治療には低血糖症治療薬が含まれ、胃腸の不調、乳酸アシドーシス、ホモシステイン値の上昇、体重増加、うっ血性心不全、浮腫など、さまざまな治療法に伴う副作用があります。

COVID-19影響分析

COVID-19のパンデミックと世界各国での封鎖により、あらゆる業種の企業の財務の健全性が影響を受けています。そのため、COVID-19公衆衛生緊急事態の期間中、米国食品医薬品局（FDA）は、スポンサーと研究者を支援し、試験参加者の安全を確保し、適正臨床実施基準（GCP）を遵守し、試験の完全性に対するリスクを最小限に抑えるための一般的な考慮事項を含むガイドラインを発表しました。

ロシア・ウクライナ戦争の影響分析

ロシアとウクライナの抗争は、世界の多嚢胞性卵巣症候群市場に与える影響は小さいと考えられています。しかし、ロシア軍からの襲撃に耐え続けるウクライナの診療所は、死亡者数の増加と特定の医療補助に押されています。

あらゆる種類の薬が不足しています。繰り返しますが、基本的な材料の輸出入の結果は、予測期間における世界の多嚢胞性卵巣症候群市場の成長にわずかな影響を与えると予測されています。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 新興国市場の開拓の増加
    • 普及率の高まり
  • 抑制要因
    • 副作用
  • 機会
    • 研究資金の増加
  • 影響分析

第5章 産業分析

• ポーターの5フォース分析
• サプライチェーン分析
• 価格分析
• 規制分析

第6章 COVID-19分析

第7章 治療タイプ別

• 薬物治療
  • 避妊薬
  • インスリン感受性改善剤
  • 抗うつ薬
  • 抗肥満薬
  • その他の薬物クラス
• 外科的治療
  • 卵巣楔状切除術
  • 腹腔鏡下卵巣穿孔術
  • その他の手術

第8章 エンドユーザー別

• 病院
• 専門クリニック
• その他

第9章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • その他アジア太平洋地域
• 中東およびアフリカ
  • 主な地域別ダイナミクス

第10章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A分析

第11章 企業プロファイル

• Pfizer Inc
  • 会社概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な発展
• Bayer AG
• Teva Pharmaceutical Industries Limited
• Novartis
• Takeda Pharmaceutical Company Limited
• Abbvie
• Ferring BV
• Merck KGaA
• EffRx, Inc
• Bristol-Myer Squibb Company

第12章 付録

Market Overview

The Global Polycystic Ovary Syndrome Market reached US$ 3.1 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 4.6 billion by 2030. The Global Polycystic Ovary Syndrome Market is expected to exhibit a CAGR of 5.5% during the forecast period 2023-2030.

The increasing cases of polycystic ovary syndrome, increase in the prevalence of risk factors, growing awareness, funding initiatives, increasing search activities, favorable reimbursement policies, and market developments such as product launches, product authorizations, alliances, acquisitions, coalitions, and expansion among others are expected to boost the Global Polycystic Ovary Syndrome Market growth in the forecast period. The key market players in this market include Bayer AG, Pfizer Inc, Teva Pharmaceutical Industries Limited, Novartis, and Takeda Pharmaceutical Company Limited, among others.

Market Dynamics

Increasing Cases of Polycystic Ovary Syndrome Drive The Growth Of The Polycystic Ovary Syndrome Market.

Polycystic ovarian syndrome (PCOS) is a typical endocrine/hormonal condition that impacts females, primarily after puberty. Alternatively, PCOS might be developed as polycystic ovary syndrome. About 5-15% of females in the reproductive age class encounter hormonal inequalities that direct to menstrual abnormalities, cysts in ovaries, infertility, and additional health issues involving cardiovascular difficulties, type 2 diabetes mellitus (T2DM), and endometrial cancer.

The World Health Organization (WHO) data indicates that roughly 116 million females (3.4%) are impacted by PCOS worldwide. Moreover, according to the PCOS Awareness Association, PCOS affects more than 7 million females in the US, which is high than the number of females diagnosed with breast cancer, rheumatoid arthritis, multiple sclerosis, and lupus combined.

The increasing research funding is Expected To Present The Global Polycystic Ovary Syndrome Market With Growth Opportunities.

The increasing research funding is presenting the global market with lucrative growth opportunities in the future. For instance, in the latest five financial years to 2019-2020, the NIHR and UKRI have granted £8.52m for an investigation into endometriosis and £6.60m for an inquiry into polycystic ovary syndrome. This encloses a broad scope of tasks from fundamental science to applied health investigation into diagnosis, therapy, and assistance delivery.

Side Effects of Treatment are Estimated To Hamper The Global Polycystic Ovary Syndrome Market During The Forecast Period.

The side effects caused by the polycystic ovary syndrome treatment hamper the global market growth during the forecast period. For instance, the polycystic ovary syndrome treatment includes hypoglycemic agents, which can lead to gastrointestinal upset, lactic acidosis, increase in homocysteine levels, weight gain, congestive heart failure, and edema, among other side effects associated with different treatment options.

COVID-19 Impact Analysis.

The financial health of companies across all industries has been impacted by the COVID-19 pandemic and lockdown in numerous nations worldwide. Therefore, for the period of the COVID-19 public health emergency, the U.S. Food and Drug Administration (FDA) issued guidelines that include general considerations to aid sponsors and researchers, ensuring the safety of trial participants, adhering to good clinical practice (GCP), and minimizing risks to trial integrity.

Russia-Ukraine War Impact Analysis.

The Russia-Ukraine brawl is considered to carry minimal impact on the global polycystic ovary syndrome market as the low prevalence and dearth of critical market players in this region. Yet, persisting to countenance raids from Russian troops, Ukrainian infirmaries are pushed by increasing numerals of deaths and specified medical aids.

There are deficiencies across all kinds of drugs. Again, the consequence of the import and export of basic materials are predicted to have a small influence on the global Polycystic Ovary Syndrome market growth in the forecast period.

Segment Analysis

The Global Polycystic Ovary Syndrome Market is segmented based on treatment type, end-user, and region.

Owing To The Increasing Research Investments Surgical Treatment Segment Is Estimated To Hold About 34.1% Of The Global Market Share By 2030.

Owing to the benefits of surgical treatment in patients not responding to drug treatment, surgical treatment is estimated to hold 34.1% of the global market share by 2030. For instance, according to the NHS, a nominal surgical process called laparoscopic ovarian drilling (LOD) might be a therapy choice for fertility issues related to PCOS that do not react to the medicine.

Geographical Analysis

Europe is Estimated to Hold 26.3% of the Market Share Owing to the Growing Polycystic Ovary Syndrome Prevalence in this Region.

Owing to the increasing prevalence and active research projects the Europe region is estimated to hold the second-largest share of the global market, accounting for about 26.3% of the total market share by 2030. For instance, according to the NHS, it is challenging to understand precisely how many females have PCOS, though it is presumed to be highly typical, impacting around 1 out of 10 females in the UK. Over 50% of these females do not encounter any manifestations.

Moreover, the EU-funded SPIOMET4HEALTH project strives to estimate an innovative practice concentrating on the additive outcomes of SPIOMET's elements. The project desires to deliver the first large-scale proof of tried medicines' psychosocial advantages and contribute to responsible decision-making regarding PCOS across European healthcare systems.

Competitive Landscape

The major global players in the polycystic ovary syndrome market include: Bayer AG, Pfizer Inc, Teva Pharmaceutical Industries Limited, Novartis, Takeda Pharmaceutical Company Limited, Abbvie, Ferring BV, Merck KGaA, EffRx, Inc., among others.

Why Purchase the Report?

• To visualize the Global Polycystic Ovary Syndrome Market segmentation based on treatment type, end-user, and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous polycystic ovary syndrome market-level data points with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of critical products of all the major players.

The Global Polycystic Ovary Syndrome Market Report Would Provide Approximately 53 Tables, 54 Figures And 195 pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Treatment Type
• 3.2. Snippet by End-user
• 3.3. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing Market Developments
    • 4.1.1.2. Growing Prevalence
  • 4.1.2. Restraints
    • 4.1.2.1. Side Effects
  • 4.1.3. Opportunity
    • 4.1.3.1. Increasing Research Fundings
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's 5 Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID-19
  • 6.1.2. Scenario During COVID-19
  • 6.1.3. Scenario Post COVID-19
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During the Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Treatment Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 7.1.2. Market Attractiveness Index, By Treatment Type
• 7.2. Drug Treatment *
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.2.3. Contraceptives
  • 7.2.4. Insulin-sensitizing Agent
  • 7.2.5. Antidepressants
  • 7.2.6. Anti-obesity
  • 7.2.7. Other Drug Classes
• 7.3. Surgical Treatment
  • 7.3.1. Ovarian Wedge Resection
  • 7.3.2. Laparoscopic Ovarian Drilling
  • 7.3.3. Other Surgeries

8. By End-user

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  • 8.1.2. Market Attractiveness Index, By End-user
• 8.2. Hospitals *
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Specialty Clinics
• 8.4. Others

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.2.5.1. The U.S.
    • 9.2.5.2. Canada
    • 9.2.5.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.3.5.1. Germany
    • 9.3.5.2. The U.K.
    • 9.3.5.3. France
    • 9.3.5.4. Spain
    • 9.3.5.5. Italy
    • 9.3.5.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.4.5.1. Brazil
    • 9.4.5.2. Argentina
    • 9.4.5.3. Rest of South America
• 9.5. Asia-Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.5.5.1. China
    • 9.5.5.2. India
    • 9.5.5.3. Japan

Australia

• 9.5.5.4. Rest of Asia-Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Market Positioning/Share Analysis
• 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

• 11.1. Pfizer Inc *
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Financial Overview
  • 11.1.4. Key Developments
• 11.2. Bayer AG
• 11.3. Teva Pharmaceutical Industries Limited
• 11.4. Novartis
• 11.5. Takeda Pharmaceutical Company Limited
• 11.6. Abbvie
• 11.7. Ferring BV
• 11.8. Merck KGaA
• 11.9. EffRx, Inc
• 11.10. Bristol-Myer Squibb Company

LIST NOT EXHAUSTIVE

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us